ArticleInternational journal of clinical and experimental pathology2018
JARID1B modulates breast cancer cell apoptosis by regulating p53 expression.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- The emerging roles of histone demethylases in cancers.Cancer metastasis reviews · 2024Review
- Adenosine receptors in breast cancer.Molecular biology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jumonji AT-rich interactive domain 1B (JARID1B) has been implicated in breast cancer progression, but its role in apoptosis has not been explored. The present study was designed to investigate the effect of JARID1B on breast cancer cell apoptosis. Apoptosis was assessed by TUNEL, flow cytometry and caspase-3 activity. JARID1B and p53 expression were examined by Western blot. Cell viability was measured by an MTT assay. We found that JARID1B is overexpressed in the breast cancer cell line and in breast cancer tissues. Upregulated expression of JARID1B in breast cancer tissues correlates with poor patient prognosis. The apoptosis of breast cancer cells is significantly increased by RNA interference targeting JARID1B. Moreover, the expression of p53 is modulated by JARID1B; the silencing of JARID1B exhibits greatly increased p53 expression at the protein level. The inhibition of p53 by small interfering RNA (siRNA) reverses the JARID1B siRNA-induced increase of apoptosis. Our results collectively suggest that JARID1B plays a key role in breast cancer cell apoptosis, and it may partially achieve this role through p53.
Indexed as
Identifiers
31949850PMC6962977W3026063970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.